Literature DB >> 17015901

PET of human prostate cancer xenografts in mice with increased uptake of 64CuCl2.

Fangyu Peng1, Xin Lu, James Janisse, Otto Muzik, Anthony F Shields.   

Abstract

UNLABELLED: Our objective was to determine whether human prostate cancer xenografts in mice can be localized by PET using 64CuCl2 as a probe (64Cu PET).
METHODS: Athymic mice bearing human prostate cancer xenografts were subjected to 64Cu PET, followed by quantitative analysis of the tracer concentrations and immunohistochemistry study of human copper transporter 1 expression in the tumor tissues.
RESULTS: Human prostate cancer xenografts expressing high levels of human copper transporter 1 were well visualized on the PET images obtained 24 h after injection but not on the images obtained 1 h after injection. PET quantitative analysis demonstrated a high concentration of 64CuCl2 in the tumors in comparison to that in the left shoulder regions (percentage injected dose per gram of tissue: 3.6 +/- 1.3 and 0.6 +/- 0.3, respectively; P = 0.004), at 24 h after injection.
CONCLUSION: The data from this study suggested that locally recurrent prostate cancer might be localized with 64Cu PET using 64CuCl2 as a probe.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17015901

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  37 in total

Review 1.  Non-standard PET radionuclides: time to get ready for new clinical PET strategies.

Authors:  Giovanni Lucignani
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-02       Impact factor: 9.236

Review 2.  PET and SPECT imaging of melanoma: the state of the art.

Authors:  Weijun Wei; Emily B Ehlerding; Xiaoli Lan; Quanyong Luo; Weibo Cai
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-10-30       Impact factor: 9.236

Review 3.  Positron emission tomography imaging using radiolabeled inorganic nanomaterials.

Authors:  Xiaolian Sun; Weibo Cai; Xiaoyuan Chen
Journal:  Acc Chem Res       Date:  2015-01-30       Impact factor: 22.384

Review 4.  Molecular imaging and therapy targeting copper metabolism in hepatocellular carcinoma.

Authors:  Jason Wachsmann; Fangyu Peng
Journal:  World J Gastroenterol       Date:  2016-01-07       Impact factor: 5.742

5.  Reduced 64Cu uptake and tumor growth inhibition by knockdown of human copper transporter 1 in xenograft mouse model of prostate cancer.

Authors:  Huawei Cai; Jiu-sheng Wu; Otto Muzik; Jer-Tsong Hsieh; Robert J Lee; Fangyu Peng
Journal:  J Nucl Med       Date:  2014-03-17       Impact factor: 10.057

6.  Positron emission tomography of human hepatocellular carcinoma xenografts in mice using copper (II)-64 chloride as a tracer with copper (II)-64 chloride.

Authors:  Haiyuan Zhang; Huawei Cai; Xin Lu; Otto Muzik; Fangyu Peng
Journal:  Acad Radiol       Date:  2011-12       Impact factor: 3.173

7.  Leveraging γ-Glutamyl Transferase To Direct Cytotoxicity of Copper Dithiocarbamates against Prostate Cancer Cells.

Authors:  Subha Bakthavatsalam; Mark L Sleeper; Azim Dharani; Daniel J George; Tian Zhang; Katherine J Franz
Journal:  Angew Chem Int Ed Engl       Date:  2018-08-29       Impact factor: 15.336

8.  Studies of copper trafficking in a mouse model of Alzheimer's disease by positron emission tomography: comparison of 64Cu acetate and 64CuGTSM.

Authors:  Erica M Andreozzi; Julia Baguña Torres; Kavitha Sunassee; Joel Dunn; Simon Walker-Samuel; Istvan Szanda; Philip J Blower
Journal:  Metallomics       Date:  2017-11-15       Impact factor: 4.526

9.  PET imaging of VPAC1 expression in experimental and spontaneous prostate cancer.

Authors:  Kaijun Zhang; Mohan R Aruva; Nylla Shanthly; Christopher A Cardi; Satish Rattan; Chirag Patel; Christopher Kim; Peter A McCue; Eric Wickstrom; Mathew L Thakur
Journal:  J Nucl Med       Date:  2007-12-12       Impact factor: 10.057

10.  Positron emission tomography for measurement of copper fluxes in live organisms.

Authors:  Fangyu Peng
Journal:  Ann N Y Acad Sci       Date:  2014-03-14       Impact factor: 5.691

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.